Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This survey is performed to examine if during the Covid's crisis, the practitionner's have respected the modalities of the law about the end of life, in particular concerning limitations and stop of therapeutics
Description: The conformity of the modalities of the decisions of limitations and therapeutic stops will be evaluated by a composite criterion defined by the simultaneous presence of the 3 main modalities imposed by the Clayes-Leonetti law to achieve a limitation that are : An outside consultant's opinion ( required if no advance directives), the caregiver collegial discussion or adherence to patient advance directives, notification of decision in the medical record
Measure: decisions of limitations and therapeutic stops Time: at the end of patient's hospitalization, an average of one monthDescription: notification of the decision, the conclusions of the discussions, the opinion of the consultant and the arguments given to justify the LAT
Measure: Characteristics of the notification of LAT procedure Time: at the end of patient's hospitalization, an average of one monthDescription: number and status of caregivers who participated to the collegial discussion
Measure: Characteristics of the LAT procedure (persons who participated to the collegial discussion) Time: at the end of patient's hospitalization, an average of one monthDescription: formal elements of the consultant's reasoned opinion ( legal term) in the file
Measure: Characteristics of consultant's reasoned opinion for the LAT procedure Time: at the end of patient's hospitalization, an average of one monthDescription: formal elements of advance directives
Measure: Characteristics of the LAT procedure Time: at the end of patient's hospitalization, an average of one monthDescription: number of beds, number of caregivers (medical, paramedical, internal external), number of admissions during periods of study
Measure: Characteristics of units Time: day 0Description: measured in year
Measure: Age of physicians Time: Day 0Description: male or female
Measure: gendrer of physicians Time: Day 0Description: Measured in year of experience
Measure: Exparience of physicians Time: Day 0Description: professional status
Measure: Characteristics of physicians Time: Day 0Description: measured in year
Measure: Age of patients Time: day 0Description: comorbidities
Measure: patient's history Time: day 0Description: COVID19 infection (yes or no)
Measure: COVID-19 patient's status Time: day 0Description: hospitalization reason
Measure: Characteristics of hospitalization's patients Time: day 0Description: organ failure
Measure: Characteristics of affected organ Time: day 0Description: severity score
Measure: Characteristics of patients Time: day 0Description: fate
Measure: final patient status Time: day 0Description: family presence or relatives
Measure: patient's environnement Time: day 0Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports